Huifeng Bio-Pharmaceutical (HFGB) Enters into Letter of Intent with Xi'an Qinba Xintong Medical Ltd.

"As a manufacturer of finished medical devices, Qinba will give Huifeng immediate access to pharmacy and medicine buyers," stated Huifeng's CEO and founder Jing'An Wang. "With this Letter of Intent, Huifeng has taken the first step toward positioning itself for synergistic growth beyond its core revenue base."

Mr. Wang further noted that Huifeng is now commencing a vertical integration strategy intended to transform the company from a producer of raw materials for the Traditional Chinese Medicine industry to a full-scale pharmaceutical company supplying end products to consumers worldwide.

"With this Letter of Intent, we have proven our ability to attract accretive deals withinthe People's Republic of China," continued Mr. Wang. "Moving forward, we hope to close on several larger strategic partnerships."

Huifeng is maintaining its guidance for $18M in revenue and $4M of net income.

About Huifeng Bio-Pharmaceutical Technology, Inc. (HFGB)

Huifeng Bio-Pharmaceutical Technology, Inc., located inXi'an,People's Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties in Xi'an China. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. http://www.hfgb.cn/

This press release may contain forward-looking statements. These statements are based on the current expectations or beliefs of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements, including but not limited to the fluctuation of prices of raw materials, the market demand for our products, changes in governmental regulations and/or economic policies and our ability to penetrate new markets.

    For more information, please contact:

    Dan Carlson, Primary Capital LLC
    Email: DCarlson@PrimaryLLC.com
    Kelly Black, CEO Premier Media Services, Inc.
    Tel:   +1-480-649-8224
    Email: kblack@premiermediaserice.com

SOURCE Huifeng Bio-Pharmaceutical Technology, Inc.